Incremental cost effectiveness ratio for the mortality (percentage) from an extended health care perspective (inclusive of implementation costs). by Natasha K. Brusco (6562550)

Subjects:

Predicted increase in monthly expenditure associated with a range of baseline characteristics in participants with poorly controlled asthma ($AU). by Stella T. Lartey (6190913)

Subjects:

Under increasing cost of feeding, females exceed males in intra-individual variability, but not inter-individual variability. by Benjamin Smarr (6954614)

“…Inter- and intra-individual variability significantly decreases with increasing food cost.</p>…”

Descriptive statistics for total cumulative study treatment costs. by Phoebe K. McCutchan (12042038)

Subjects:

The Pareto chart with the 30 most significant factors on the number of steps before a fall across all three speeds. by Amy Mitchell (3208905)

Subjects:

Nasal microbiota features significantly associate with the presence of clinical signs. by Holly Kristin Arnold (14204655)

Gut microbiota features significantly associate with the presence of clinical signs. by Holly Kristin Arnold (14204655)

Sobel test and bootstrap method to test significance of mediation effects. by Cheyuan Liu (19859517)

Communication overhead in the network with increasing number of users. by Ghulam Abbas (764241)

Dynamic decryption cost. by Salim Sabah Bulbul (18446545)

“…The scheme outperforms existing ones, reducing server-side search costs significantly.</p></div>…”

Current and potential barriers to discussion of costs in clinics by oncologists. by Anupriya Agarwal (262443)

Calculated costs per phase. by Chin-Ling Chen (17542074)

Subjects:

Communication costs per phase. by Chin-Ling Chen (17542074)

Subjects:

Total costs (treatment costs and premature mortality) among population with overweight and obesity in 2020 and 2021 (in 2020 constant USD). by Adeyemi Okunogbe (9101644)

Subjects:

Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4. by Naoya Itoh (6029276)

Subjects:

Supplementary data: Healthcare cost and utilization before and after the development of significant tricuspid regurgitation by age, sex and race by David P Cork (22827543)

“…<b>Results:</b> Costs and utilization increased in the 3 years leading up to and the year after sTR. …”

Changes in TEER and permeability of EA.hy926 cells exposed to EVs or pellets from infected or uninfected macrophages. by Myriam Lucia Velandia-Romero (8259726)

“…Interestingly, TEER increased significantly (up to 15 Ω/cm²) when EA.hy926 cells were exposed to EVs obtained from infected U937 macrophages (<i>EV (+)</i>_<i>4G2</i> or <i>P(+))</i> (B). …”

Intangible cost of breast cancer treatments. by Kekeli Kodjo Adanu (12218897)

Subjects:

Estimated cost production of L-500. by Camilo C. Castro-Jiménez (20536059)

Formulae for the cost estimation. by Heejin Choi (621081)

“…Furthermore, as climate change intensifies, tick populations are projected to increase, leading to a rise in control costs and SFTS cases. …”